Print this page
myeloma
-
Impact of Early Radiation Oncology Involvement as Part of a Multidisciplinary Palliative Care Team on Quality of Life Among Diverse Patients with Advanced/Metastatic Malignancies.
Protocol: 002168Principal Investigator:
-
Malcolm Mattes
Applicable Disease Sites: Any Site -
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma.
Protocol: 011909Principal Investigator:
-
Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization.
Protocol: 011910Principal Investigator:
-
Mansi R Shah
Applicable Disease Sites: Bones and Joints
Ill-Defined Sites
Multiple Myeloma -
Machine Learning-based High-throughput and Integrative Immunological Synapse Quality Evaluation As a Composite Biomarker for Predicting CAR Therapy Efficacy in Immuno-Oncology.
Protocol: 012108Principal Investigator:
-
Yun Kyoung Tiger
Applicable Disease Sites: Hodgkin's Lymphoma
Multiple Myeloma
Non-Hodgkin's Lymphoma -
A Long-Term Study for Participants Previously Treated With Ciltacabtagene Autoleucel.
Protocol: 012204Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Multiple Myeloma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
-
Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
Testing of Immune Synapse Characteristics During Therapy of Multiple Myeloma
Protocol: 012322Principal Investigator:
-
Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials.
Protocol: 022404Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia.
Protocol: 022404-MM1OA-EA0Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial).
Protocol: 022404-MM1YA-CTGPrincipal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia.
Protocol: 022404-MM1YA-S01Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metastases: A Phase II Study.
Protocol: 152201Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Any Site